Real-World Relationship of Early End Points to Survival End Points in Patients with Resectable Non-Small-Cell Lung Cancer

References

• Morgensztern D , NgSH, GaoF, GovindanR. Trends in stage distribution for patients with non-small-cell lung cancer: a National Cancer Database survey. J. Thorac. Oncol.5(1), 29–33 (2010).
   PubMed Web of Science ®Google Scholar
• Uramoto H , TanakaF. Recurrence after surgery in patients with NSCLC. Transl. Lung Cancer Res.3(4), 242–249 (2014).
   PubMedGoogle Scholar
• al-Kattan K , SepsasE, FountainSW, TownsendER. Disease recurrence after resection for stage I lung cancer. Eur. J. Cardiothorac. Surg.12(3), 380–384 (1997).
   PubMed Web of Science ®Google Scholar
• Su S , ScottWJ, AllenMSet al. Patterns of survival and recurrence after surgical treatment of early stage non-small-cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. J. Thorac. Cardiovasc. Surg.147(2), 747–752; discussion 752–743 (2014).
   PubMed Web of Science ®Google Scholar
• Martini N , BainsMS, BurtMEet al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg.109(1), 120–129 (1995).
   PubMed Web of Science ®Google Scholar
• Fedor D , JohnsonWR, SinghalS. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg. Oncol.22(3), 156–161 (2013).
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-analysis Collaborative Group . Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet383(9928), 1561–1571 (2014).
   PubMed Web of Science ®Google Scholar
• Ettinger DS , WoodDE, AkerleyWet al. Non-small-cell lung cancer, version 1.2015. J. Natl Compr. Canc. Netw.12(12), 1738–1761 (2014).
   PubMed Web of Science ®Google Scholar
• Ettinger DS , AkerleyW, BeplerGet al. Non-small-cell lung cancer. J. Natl Compr. Canc. Netw.8(7), 740–801 (2010).
   PubMed Web of Science ®Google Scholar
• Lim E , HarrisG, PatelA, AdachiI, EdmondsL, SongF. Preoperative versus postoperative chemotherapy in patients with resectable non-small-cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J. Thorac. Oncol.4(11), 1380–1388 (2009).
   PubMed Web of Science ®Google Scholar
• Pisters KM , LeChevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J. Clin. Oncol.23(14), 3270–3278 (2005).
   PubMed Web of Science ®Google Scholar
• Rosell R , Gómez-CodinaJ, CampsCet al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med.330(3), 153–158 (1994).
   PubMed Web of Science ®Google Scholar
• Roth JA , FossellaF, KomakiRet al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl Cancer Inst.86(9), 673–680 (1994).
   PubMed Web of Science ®Google Scholar
• Arriagada R , AuperinA, BurdettSet al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet375(9722), 1267–1277 (2010).
   PubMed Web of Science ®Google Scholar
• Brahmer J , ReckampKL, BaasPet al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med.373(2), 123–135 (2015).
   PubMed Web of Science ®Google Scholar
• Provencio M , NadalE, InsaAet al. Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): a Phase II multicenter exploratory study—Final data of patients who underwent surgical assessment. J. Clin. Oncol.37(Suppl. 15), 8509 (2019).
   Web of Science ®Google Scholar
• Hellmann MD , ChaftJE, WilliamWNJret al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate end point. Lancet Oncol.15(1), e42–50 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Trial End points for the Approval of Non Small Cell Lung Cancer . Drugs and Biologics Guidance for Industry. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2015). https://www.fda.gov/media/116860/download (Accessed 6September2022).
   Google Scholar
• Waser NA , AdamA, SchweikertBet al. Pathologic response as early end point for survival following neo-adjuvant therapy (NEO-AT) in resectable non-small-cell lung cancer (rNSCLC): systematic literature review and meta-analysis (Abstract 1243P). Ann. Oncol.31(Suppl. 4), S806 (2020).
   Google Scholar
• Rosner S , LiuC, FordePM, HuC. Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis. JTO Clin Res Rep.3(9), 100384 (2022).
   PubMedGoogle Scholar
• Blumenthal GM , BunnPAJr, ChaftJEet al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J. Thorac. Oncol.13(12), 1818–1831 (2018).
   PubMed Web of Science ®Google Scholar
• Cottrell TR , ThompsonED, FordePMet al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol.29(8), 1853–1860 (2018).
   PubMed Web of Science ®Google Scholar
• American Joint Committee on Cancer . AJCC Cancer Staging Manual. Seventh Edition (2010). www.facs.org/media/j30havyf/ajcc_7thed_cancer_staging_manual.pdf (Accessed 1December2022).
   Google Scholar
• Rami-Porta R , AsamuraH, TravisWD, RuschVW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin.67(2), 138–155 (2017).
   PubMed Web of Science ®Google Scholar
• The US Oncology Network . https://www.usoncology.com/our-company
   Google Scholar
• Chan YH . Biostatistics 104: correlational analysis. Singapore Med. J.44(12), 614–619 (2003).
   PubMedGoogle Scholar
• Forde PM , SpicerJ, LuSet al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med.386(21), 1973–1985 (2022).
   PubMed Web of Science ®Google Scholar
• Provencio-Pulla M , SpicerJ, TaubeJMet al. Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small-cell lung cancer (NSCLC): association of pathological regression with event-free survival (EFS) in CheckMate 816. J. Clin. Oncol.40(Suppl. 17), LBA8511 (2022).
   Web of Science ®Google Scholar
• Kalhor N , CorreaAM. CorreaAMet al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol.7(5), 825–832 (2012).
   PubMed Web of Science ®Google Scholar
• Anderson JR , CainKC, GelberRD. Analysis of survival by tumor response. J. Clin. Oncol.1(11), 710–719 (1983).
   PubMed Web of Science ®Google Scholar
• Antonia SJ , BorghaeiH, RamalingamSSet al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol.20(10), 1395–1408 (2019).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , CiuleanuTE, PluzanskiAet al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med.378(22), 2093–2104 (2018).
   PubMed Web of Science ®Google Scholar
• Hellmann MD , Paz-AresL, BernabeCaro Ret al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med.381(21), 2020–2031 (2019).
   PubMed Web of Science ®Google Scholar
• Santi I , SmareC, Juarez-GarciaAet al. PRM157 - The Impact of Landmark Response on Overall Survival: Implications for the Economic Evaluation of Immune-Therapy (I-O) Treatment in Small Cell Lung Cancer (SCLC). Value in Health.21, S383 (2018).
   Web of Science ®Google Scholar
• Ostoros G , BerktasM, ChanderPet al. Association between event-free survival and overall survival following neoadjuvant therapy for resectable non-small-cell lung cancer. Presented at: European Society for Medical Oncology Congress.Paris, France, Poster Session 943P, 9–13 September 2022. (Accessed 3October2022). https://oncologypro.esmo.org/meeting-resources/esmo-congress/association-between-event-free-survival-and-overall-survival-following-neoadjuvant-therapy-for-non-small-cell-lung-cancer
   Google Scholar
• Counts SJ , KimAW. Diagnostic imaging and newer modalities for thoracic diseases: PET/computed tomographic imaging and endobronchial ultrasound for staging and its implication for lung cancer. Surg. Clin. North Am.97(4), 733–750 (2017).
   PubMed Web of Science ®Google Scholar
• Rami-Porta R , CallS, DoomsCet al. Lung cancer staging: a concise update. Eur. Respir. J.51(5), 1800190 (2018).
   PubMed Web of Science ®Google Scholar
• Felip E , AltorkiN, ZhouCet al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, Phase III trial. Lancet398(10308), 1344–1357 (2021).
   PubMed Web of Science ®Google Scholar